The list of health conditions that benefit from the GLP-1 weight loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound, continues to grow. The drugs are already approved to lower the risk of heart disease, sleep apnea, kidney and liver conditions. In the latest study on the medications, published in the BMJ , researchers led by Dr. Ziyad Al-Aly, from the department of medicine at the Washington University School of Medicine, report that people taking the drugs lowered their risk